• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Bristol-Myers Squibb

Bristol-Myers Squibb

VY® T. Rowe Price Equity Income S IRPSX 3 Star

Last Price$14.33Day Change (%)0.14%
Open Price$14.33Day Change ($)0.02
Day Range14.33–14.3352-Week Range12.86–14.56

As of Wed 03/29/2017 | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Bristol-Myers Squibb Names New R&D Chief

    Bristol-Myers Squibb Names New R&D Chief

  2. Bristol-Myers Squibb Appoints Dr. Thomas J. Lynch, Jr., Executive Vice President and Chief Scientific Officer

    Bristol-Myers Squibb Appoints Dr. Thomas J. Lynch, Jr., Executive Vice President and Chief Scientific Officer

  3. Bristol-Myers Squibb and Pfizer to Present New Analyses of Eliquis™ (apixaban) Clinical and Real-World Data at the American College of Cardiology 2017 Scientific Session

    Bristol-Myers Squibb and Pfizer to Present New Analyses of Eliquis™ (apixaban) Clinical and Real-World Data at the American College of Cardiology 2017 Scientific Session

  4. Bristol-Myers Squibb Announces Dividend

    Bristol-Myers Squibb Announces Dividend

  5. Bristol-Myers Squibb to Present Data That Advances Understanding of Effects of Immuno-Oncology Therapies on Cancer Biology and Patient Outcomes at AACR 2017

    Bristol-Myers Squibb to Present Data That Advances Understanding of Effects of Immuno-Oncology Therapies on Cancer Biology and Patient Outcomes at AACR 2017

  6. UPDATE: Trumpcare's collapse creates some certainty for health-care stocks

    UPDATE: Trumpcare's collapse creates some certainty for health-care stocks

  7. Trumpcare's collapse creates some certainty for health-care stocks

    Trumpcare's collapse creates some certainty for health-care stocks

  8. UPDATE: Trumpcare's collapse creates some certainty for health-care stocks

    UPDATE: Trumpcare's collapse creates some certainty for health-care stocks

  9. UPDATE: Pharma says high prices fund drug development -- but this study finds otherwise

    UPDATE: Pharma says high prices fund drug development -- but this study finds otherwise

  10. FDA nominee Scott Gottlieb plans recusals from decisions on many drug firms

    FDA nominee Scott Gottlieb plans recusals from decisions on many drug firms

12345

©2017 Morningstar Advisor. All right reserved.